Chapter 251 Side effects appear!
“Holy shit! Qingshan Pharmaceutical is so awesome, the latest treatment plan can actually achieve at least 83% of the basic treatment effect!”

“Do you know what an 83% minimum treatment effect means? It means that as long as drug resistance does not occur, the vast majority of acute leukemia patients can survive through long-term drug injections! Survive! My God, my God!”

“Haha, I’ve said it before that Qingshan Pharmaceutical is the absolute king in the research and development of blood diseases! Qingshan Pharmaceutical YYDS! The eternal god!”

“Fuck! I bow down to Qingshan Pharmaceutical. When I saw that Ibelumab only had a 50% therapeutic effect, I didn’t think it was a big deal. I didn’t expect Qingshan Pharmaceutical to make a breakthrough so quickly! So strong! I’ve been undergoing chemotherapy for three years, but I’m still not as good as one injection of Ibelumab from Qingshan Pharmaceutical!”

“That’s right, I love Qingshan Pharmaceutical, I love China! Qingshan Pharmaceutical is the only beacon of mankind!”

“Yes, Qingshan Pharmaceutical is the only hope!”

Just when the patients of the Hematology Department of Chengdu Third People’s Hospital were very dissatisfied,
Just when Pfizer was trying to create some trouble for Tsingshan Pharmaceutical, the news of “Involumab”‘s 83% basic therapeutic effect was not affected at all and quickly caused heated discussions in foreign media.

In particular, overseas patients who had already paid attention to “Ibetuzumab” were even more excited and praised Tsingshan Pharmaceutical in the media with the highest praise.

Zhang Yang also heard about the overseas hype about Qingshan Pharmaceutical, but he had no intention of paying attention to it. At this time, he and all the researchers in the first project team were closely monitoring the possible unknown side effects of the combination of “ibumaclomab” + “allogeneic T cells”.

but,

After the hotly debated news abroad was reposted in China, especially after the domestic media also followed suit and reported that “Ivacumab” was a miracle drug for treating leukemia, the families of patients who were participating in the Phase II clinical trial at Chengdu Third People’s Hospital became increasingly anxious.

did you see?
So many media outlets at home and abroad have reported on it, saying it’s a miracle drug, so how could it be fake?
Also, the subjects have been taking the medicine for half a month and have not seen any side effects!
Tsingshan Pharmaceutical deliberately does not provide us with the best treatment options.

An increasingly strong feeling of dissatisfaction hangs over the hearts of patients’ families, and more and more patients in clinical trials have actively expressed their desire to use a more advanced treatment method such as “allogeneic T cells” + “ibukumab”.

Seeing that everyone’s dissatisfaction was growing, Director Hu had no choice but to tell Zhang Yang about this matter in order to successfully complete the Phase II clinical trial.

Zhang Yang really didn’t expect that his good intentions would be misinterpreted like this.

He just wanted to first find out the side effects of the combination of “ibukumab” in patients who took the medicine independently.

Then, after the approximate side effects are understood, it will be gradually applied to other patients to ensure the safety of every patient tested to the greatest extent possible.

“Mr. Zhang, in fact, the patients and their families don’t have any other concerns. They are just anxious because they see that others are getting good treatment results while they are not.”

Seeing Zhang Yang’s pale face, Director Hu was also disheartened, but he still tried to persuade him.

Zhang Yang nodded slightly.

After a moment, he said:

“In fact, I don’t want to apply the combined treatment to double-blind test patients in such a short time.”

“After all, ‘allogeneic T cells’ have strong side effects themselves. Plus, when they are used on leukemia patients, the probability of side effects is likely to increase exponentially!”

“But… since they don’t believe me when I say that, and they insist on doing combined treatment, that’s fine!”

“Just let them sign a consent form and waiver of liability for side effects like those seriously ill patients. I’m sorry to bother you with this, Director.”

Having said that, Director Hu could only sigh and nod.

“Okay, then I’ll tell them and see what they choose.”

The dissatisfaction of the patients in the clinical trial was just a minor episode for Zhang Yang. After talking with Director Hu, he put the matter behind him.

Director Hu quickly returned to the Department of Hematology, and when the patient’s family brought up the matter again, he informed the patient that he could apply for the combined treatment of “ibuclumab” + “allogeneic T cells”.

“Really? Director.”

“Yes, but a waiver agreement and a side effect notification form must be signed. In other words, if serious side effects occur, Qingshan Pharmaceutical will have nothing to do with it.”

“Don’t worry, Director. We are not afraid of any side effects. They are fine without using any, right?”

Director Hu looked at the many ignorant patients and didn’t know what to say. Soon, several subjects signed the informed consent form for the combined treatment and medication regimen.

But just as many patients were looking forward to the next treatment, a few days later, a lot of negative news about “Ibetuzumab” suddenly broke out on foreign Internet.

“Shocking! Qingshan Pharmaceutical’s latest combination drug regimen has been revealed to potentially cause organ failure and even bone marrow stem cell failure!”

“Many biological experts said that the combination therapy of ‘allogeneic T cells’ and ‘ibukumab’ is not reliable and is extremely risky!”

“Qingshan Pharmaceutical’s latest miracle drug for treating leukemia, ‘Ibetumumab’, may be discontinued…”

“According to our newspaper, today we have contacted Tsingshan Pharmaceutical as soon as possible, but as of press time, Tsingshan Pharmaceutical has not responded to the current online news.”

As soon as the news came out, domestic netizens were confused about the situation.

Didn’t the Internet just report a few days ago that Tsingshan Pharmaceutical’s “Ibetumumab” was invincible? How come it is now reported to have side effects?

Is “Ibetumumab” strong or does it have side effects?
Whatever you think comes true, right?
but.

When the news was forwarded to major leukemia patient communication groups in China, several patients and their families who had already signed up for the “Ibetuzumab” combination treatment plan were stunned.

“My goodness, what Director Hu said can’t be true? Can it really have strong side effects?”

“Uh… Dad, should we reconsider this? Should we not participate in this joint treatment plan for the time being?”

“Yes! Let’s go find Director Hu and see if we can cancel it…”

Half an hour later.

Many of the patients who had caused the most trouble before knocked on Director Hu’s office door.

“Director, I’m sorry. We were wrong. We misunderstood Qingshan Pharmaceutical’s kindness. We were wrong. We apologize!”

“Can we not do combined treatment for the time being?”

Director Hu snorted coldly:
“hehe.”

……

The changing attitudes of the subjects at Chengdu Third People’s Hospital were just an episode that could not be any smaller for Zhang Yang.

At this time, he noticed a lot of news about the side effects of “Ibetumumab” on the Internet at home and abroad.

In the office, Zhang Yang held a gel pen between his fingers and tapped the table lightly.

“Wei Tian, ​​who do you think spread the news about our ‘Ibeumab’ having side effects? These side effects reported are still in the verification stage for us, but they were able to clearly point them out at a glance, which is not easy!”

“Yes, boss. I think it was leaked to the media by a pharmaceutical company in the industry. It’s unlikely to be a domestic pharmaceutical company. It’s most likely a foreign pharmaceutical company.”

“Foreign pharmaceutical companies? But what motive do they have for doing this?!”

Zhang Yang was a little confused.

Wei Tian also shook his head, with a hint of doubt on his face:
“I don’t know either. Is it possible that we’ve been too popular recently, so they want to suppress us?”

“Or maybe they have drugs that compete with ours, and seeing that ‘Ivolumab’ is touted as the number one drug for leukemia on the Internet, they want to… create some trouble for us?” “It’s possible!”

Zhang Yang nodded, and a trace of solemnity suddenly appeared on his face.

“Moreover, if the combination of ‘ibuzumab’ and ‘allogeneic T cells’ is really as they say, there is a high probability of causing bone marrow failure, which will be a very troublesome thing for us.”

“This may mean that the combination therapy of ‘Ivolumab’ cannot be implemented, and the sales of our ‘Ivolumab’ after it is launched in the future will definitely be affected.”

“However, don’t worry too much. We don’t know if the combination therapy with ‘ibumaxin’ has any side effects, so we need to monitor it!”

“Too!”

Zhang Yang’s relief did not last long.

In other words, as one of the top five pharmaceutical companies in the world, Pfizer does have something.

Just three weeks after Qingshan Pharmaceutical’s “Ibetuzumab” was used in combination therapy for patients who were taking the drug independently, as Pfizer predicted, side effects caused by the activation of “acute rejection reaction” by long-term injection of “allogeneic T cells” appeared.

After receiving the call, Zhang Yang quickly came to the conference room of Qingshan Pharmaceutical R&D Center.

Wei Tian, ​​Dr. Zhou and several team leaders have been waiting for a long time.

Wei Tian hurriedly handed the latest clinical data sent by the Third People’s Hospital to Zhang Yang with a serious expression.

“Boss, the latest clinical examination report results are out.”

“Bed 79, the patient named Liu Xiaochuan, showed obvious abnormalities in his blood count. His platelet count dropped from the normal median three weeks ago to below the normal level now.”

“In addition, the patient’s red blood cells and white blood cells also decreased significantly, which is a typical hematopoietic dysfunction.”

“And the results of his latest bone marrow puncture have also come out, and the bone marrow hematopoietic stem cells have shown obvious depletion.”

Zhang Yang quickly took the patient examination report handed over by Wei Tian.

To be honest, he had already imagined such a situation countless times in his mind, but when a patient with such serious side effects actually appeared, he still felt helpless.

“How is the patient now?”

“The patient is in good condition now. I have instructed my colleagues in charge of clinical medication in the hospital to suspend Liu Xiaochuan’s ‘allogeneic T cell’ injection, but ‘ibuzumab’ will continue to be used.”

“I have a deep impression of this patient. I remember that he had good results when he used ‘ibuzumab’ alone for treatment before, with a treatment effect of about 73%. So, it is not a problem to control leukemia in a short period of time.”

“At the same time, I have discussed this with Director Hu. As his blood count is currently low, Director Hu suggested that we add Qingshan Avatrombopag Tablets to stabilize his blood count first.”

“However, until now he still doesn’t know that his bone marrow hematopoietic stem cells have failed, and we are all waiting for the right time to tell him about it.”

At the end, Wei Tian’s tone became a little depressed.

Zhang Yang also sighed slightly. Sometimes modern medicine is like this. While treating a disease, one must bear the side effects of the treatment.

Just like now, the leukemia is under control, but the bone marrow’s hematopoietic ability is having problems again.

“Well, tell me the truth. Although the truth is a bit cruel, there is nothing we can do about it.”

“Also, give patients more compensation after the clinical trial is over.”

“Ok.”

Wei Tian nodded and agreed.

Seeing this, Zhang Yang let out a breath and looked at Dr. Zhou who had been silent.

He now has a basic understanding of the current situation, and it is time to discuss the next issue!
After a brief pause, he said:
“Zhou Bo, the combined treatment has shown serious adverse reactions. What are your plans next?”

“Most importantly, should we suspend the combined treatment plan for the remaining 31 subjects?”

Zhang Yang’s question can be said to be very sharp and realistic.

But as the leader of the “Ibetumumab” project, Dr. Zhou naturally has to deal with all problems.

Fortunately, Dr. Zhou had obviously thought about this problem a long time ago. He paused for a moment and said in a deep voice:
“Mr. Zhang, although we have already considered that the long-term activation of ‘allogeneic T cells’ and ‘acute rejection reaction’ may cause bone marrow stem cell damage to bone marrow transplant patients, I have to say that in a trial of 32 people, such serious side effects in just three weeks are beyond my expectations!”

“So, if we look at it from a scientific perspective, the probability of this side effect is actually not low!”

“So, from the perspective of patient safety, I would prefer to suspend the combination therapy of ‘ibuzumab’ + ‘allogeneic T cells’ to prevent more subjects from experiencing such bone marrow failure.”

“But in this case, at least 83% of the therapeutic effect of the current combined treatment plan will definitely not be achieved!”

Zhang Yang also sighed helplessly and said:
“There’s nothing we can do about it. We can’t let the patient suffer from bone marrow failure just to treat leukemia, right?”

“Okay, Zhou Bo, have you thought of any other alternatives?”

“No.”

Dr. Zhou shook his head slightly.

“The reason why we considered using ‘allogeneic T cells’ before was to activate the body’s ‘acute rejection reaction’, thereby increasing the metabolic rate of immune cells.”

“Injection of ‘allogeneic T cells’ is now the most mainstream and safest method, otherwise we would not have thought of it in the first place.”

“I have seen and understood other methods. They are difficult and the technology is not mature yet.”

“So… there may not be a breakthrough in the short term.”

Zhang Yang also fell silent. He was also involved in the entire process of conceiving the “ibumazumab” combination treatment plan.

If there really was a better way, I would have thought of it at the first moment, why would I bring it up only now?

The conference room suddenly became a little dull. The 83% effective treatment rate achieved by the combination therapy of “ibukumab” + “allogeneic T cells” now seemed to be just a flash in the pan.

But just when the atmosphere was a little low, Wei Tian beside him suddenly coughed lightly.

“Boss Zhang, I have something else I want to report.”

“This morning when I went to the hospital to get the clinical data results, Director Hu and I had a brief conversation.”

“He carefully read the patient’s bone marrow puncture report and blood count indicators, and gave a suggestion. He said that Liu Xiaochuan could try our ‘ITG human myelopoietin’ to see if it could cure this side effect!”

ITG human myelopoietin? !

Curing bone marrow failure side effects? !

(End of this chapter)